당뇨병성 신경병증 치료 시장 : 질병 유형별, 약물 종류별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Diabetic Neuropathy Treatment Market size was valued at USD 4,390.32 Million in 2023, expanding at a CAGR of 8.10% from 2024 to 2032.

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes, usually because of prolonged high blood sugar levels. Treatment typically focuses on managing symptoms and preventing further nerve damage.

Diabetic Neuropathy Treatment Market- Market Dynamics

Improved diagnostic techniques in diabetes treatment and innovative therapies are expected to propel market demand

The growing incidence of diabetes, particularly type 2 diabetes, worldwide is a key driver of the market growth. As the number of diabetes patients increases, so does the demand for effective treatments for complications such as diabetic neuropathy. Advances in diagnostic technologies and increased awareness lead to earlier and more accurate diagnosis of diabetic neuropathy. Early diagnosis often leads to better management and treatment outcomes, increasing the demand for therapies. Higher healthcare spending and improved healthcare infrastructure in emerging markets contribute to the growth of the diabetic neuropathy treatment market.

Increasing investment into research & new treatments and therapies, including novel pharmaceuticals, biologics, and medical devices, contributes to market growth. Innovations in drug delivery systems and therapeutic approaches enhance treatment options. Government initiatives and funding for diabetes research and treatment, as well as favorable reimbursement policies for diabetic neuropathy therapies, support market growth. The introduction of new drugs and therapies into the market, including those targeting specific neuropathic pain pathways or providing better efficacy and safety profiles, drives market growth.

Diabetic Neuropathy Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.10% over the forecast period (2024-2032)

Based on Disease Type segmentation, the peripheral neuropathy segment was predicted to show maximum market share in the year 2023, as it is one of the most common forms of diabetic neuropathy.

Based on Drug Class segmentation, the non-steroidal anti-inflammatory drugs (NSAIDs) segment was the leading Drug Class in 2023, due to its affordability in the market.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel in 2023, owing to high medication at hospital pharmacies.

On the basis of region, North America was the leading revenue generator in 2023, owing to the presence of developed healthcare infrastructure for diabetic treatment.

Diabetic Neuropathy Treatment Market- Segmentation Analysis:

The Global Diabetic Neuropathy Treatment Market is segmented on the basis of Disease Type, Drug Class, Distribution Channel, and Region.

The market is divided into four categories based on Disease Type: peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment dominates the market. The high prevalence of diabetes among old adults is boosting segment demand.

The market is divided into four categories based on Drug Class: capsaicin, opioid, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), and others. The Non-Steroidal Anti-inflammatory Drugs (NSAIDs) segment is projected to hold the largest share of the market. The opioid segment is estimated to grow at the fastest rate over the forecast period. Opioids are potent analgesics that can provide more effective pain relief.

The market is divided into three categories based on Distribution channels: hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. Hospital pharmacies have an integrated system for managing medications, which makes it easier to process and hence have greater adoption.

Diabetic Neuropathy Treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, predominantly the United States, holds a significant share of the global diabetic neuropathy treatment market due to a high prevalence of diabetes and advanced healthcare infrastructure. The Asia-Pacific region, including countries like China and India, is experiencing rapid growth in the diabetic neuropathy treatment market due to rising diabetes rates and improving healthcare infrastructure.

Diabetic Neuropathy Treatment Market- Competitive Landscape:

The diabetic neuropathy treatment market is moderately competitive, with numerous companies involved in developing and offering diabetic treatment solutions. Market players are working on novel drugs targeting specific pain pathways associated with diabetic neuropathy including new formulations and targeted therapies. Companies are increasingly focusing on emerging markets such as Asia-Pacific and Latin America due to the rising prevalence of diabetes and expanding healthcare infrastructure.

Recent Developments:

In December 2023, Vertex Pharmaceuticals got FDA approval for CRISPR-based gene editing therapy, a strategic move which focuses on the development of non-opioid pain management drugs.

In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, has launched a treatment for Diabetic Neuropathy, a condition causing nerve damage.

In 2022, Axovant Gene Therapies is exploring advanced treatments including gene and cell therapies for neurological conditions.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET KEY PLAYERS

• Pfizer Inc.
• Eli Lilly and Company
• Astellas Pharma Inc.
• GlaxoSmithKline plc.
• Boehringer Ingelheim
• NeuroMetrix Inc.
• Axovant Gene Therapies Ltd.
• Eton Pharmaceuticals
• Alnylam Pharmaceuticals
• Novartis International AG
• Sanofi
• Johnson & Johnson
• Amgen Inc.
• AbbVie Inc.
• Merck & Co.
• Vertex Pharmaceuticals
• Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019-2032

• Peripheral neuropathy
• Autonomic neuropathy
• Proximal neuropathy
• Focal neuropathy

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019-2032

• Capsaicin
• Opioid
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

• Hospital Pharmacies
• Retail Pharmacies
• Others

GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Diabetic Neuropathy Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Diabetic Neuropathy Treatment Market Snippet by Disease Type
  • 2.1.2. Diabetic Neuropathy Treatment Market Snippet by Drug Class
  • 2.1.3. Diabetic Neuropathy Treatment Market Snippet by Distribution Channel
  • 2.1.4. Diabetic Neuropathy Treatment Market Snippet by Country
  • 2.1.5. Diabetic Neuropathy Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Diabetic Neuropathy Treatment Key Market Trends

• 3.1. Diabetic Neuropathy Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Diabetic Neuropathy Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Diabetic Neuropathy Treatment Market Opportunities
• 3.4. Diabetic Neuropathy Treatment Market Future Trends

4. Diabetic Neuropathy Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Diabetic Neuropathy Treatment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Diabetic Neuropathy Treatment Market Landscape

• 6.1. Diabetic Neuropathy Treatment Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Diabetic Neuropathy Treatment Market - By Disease Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
  • 7.1.2. Peripheral neuropathy
  • 7.1.3. Autonomic neuropathy
  • 7.1.4. Proximal neuropathy
  • 7.1.5. Focal neuropathy

8. Diabetic Neuropathy Treatment Market - By Drug Class

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
  • 8.1.2. Capsaicin
  • 8.1.3. Opioid
  • 8.1.4. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • 8.1.5. Others

9. Diabetic Neuropathy Treatment Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Retail Pharmacies
  • 9.1.4. Others

10. Diabetic Neuropathy Treatment Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Diabetic Neuropathy Treatment Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Diabetic Neuropathy Treatment Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Diabetic Neuropathy Treatment Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Diabetic Neuropathy Treatment Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Diabetic Neuropathy Treatment Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Diabetic Neuropathy Treatment Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
  • 11.2.2. Eli Lilly and Company
  • 11.2.3. Astellas Pharma Inc.
  • 11.2.4. GlaxoSmithKline plc.
  • 11.2.5. Boehringer Ingelheim
  • 11.2.6. NeuroMetrix Inc.
  • 11.2.7. Axovant Gene Therapies Ltd.
  • 11.2.8. Eton Pharmaceuticals
  • 11.2.9. Alnylam Pharmaceuticals
  • 11.2.10. Novartis International AG
  • 11.2.11. Sanofi
  • 11.2.12. Johnson & Johnson
  • 11.2.13. Amgen Inc.
  • 11.2.14. AbbVie Inc.
  • 11.2.15. Merck & Co.
  • 11.2.16. Vertex Pharmaceuticals
  • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us